SCHEMBL12439612

SCHEMBL12439612

Oc1cc(-c2ccccc2)nc2nc3ccccc3n12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 7/20 0.47
BMX P51813 2/20 0.47
KDM4E B2RXH2 7/20 0.43
ALDH1A1 P00352 5/20 0.43
HPGD P15428 4/20 0.43
GAA P10253 2/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
HSD17B10 Q99714 2/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NTSR1 P30989 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12439616 0.81 BMX (0.53) FLT3BMXKDM4EALDH1A1HPGD
SCHEMBL9362915 0.80 CSNK1A1 (0.44) FLT3BMXKDM4EALDH1A1HPGD
SCHEMBL12395170 0.78 KDM4E (0.55) FLT3KDM4EALDH1A1HPGDGAA
SCHEMBL18033193 0.76 FLT3 (0.67) FLT3BMXKDM4EALDH1A1HPGD
SCHEMBL18033282 0.76 FLT3 (0.54) FLT3BMXKDM4EALDH1A1GAA
SCHEMBL19788354 0.75 KDM4E (0.43) FLT3BMXKDM4EALDH1A1HPGD
SCHEMBL18033260 0.75 FLT3 (0.53) FLT3BMXKDM4EALDH1A1GAA
SCHEMBL18033196 0.74 FLT3 (0.55) FLT3BMXKDM4EALDH1A1HPGD
SCHEMBL18033232 0.73 FLT3 (0.57) FLT3BMXKDM4EALDH1A1HPGD
SCHEMBL18033154 0.72 FLT3 (0.50) FLT3BMXKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178107-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2011-07-21 US disclosed
US-20110178107-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178107-A1 HCV PROTEASE INHIBITORS HAVCR2, RNASE1, SERPINB1 FLT3 3614/4885BMX 3368/4885KDM4E 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.